Figure 3From: Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial Hemoglobin and reticulocyte time course, Q2W administration interval. Hb, ret and ESA dose as a function of time at 4 weeks ESAs-administration interval; C.E.R.A. black dash line, Darbepoietin alfa black solid line. Vertical lines correspond to ESA administration.Back to article page